^
    Apply
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (NCT05007418)
    Phase 1b
    Sorrento Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/16/2023
    Initiation :
    10/01/2022
    Primary completion :
    12/01/2025
    Completion :
    02/01/2026
    CD38
    |
    CD38 expression
    |
    STI-1492